Does GT Biopharma Inc (GTBP) Have What it Takes to be in Your Portfolio Thursday?

Thursday, October 14, 2021 02:32 PM | InvestorsObserver Analysts

Mentioned in this article

Does GT Biopharma Inc (GTBP) Have What it Takes to be in Your Portfolio Thursday?

GT Biopharma Inc (GTBP) is around the middle of the Biotechnology industry according to InvestorsObserver. GTBP received an overall rating of 43, which means that it scores higher than 43 percent of all stocks. GT Biopharma Inc also achieved a score of 61 in the Biotechnology industry, putting it above 61 percent of Biotechnology stocks. Biotechnology is ranked 77 out of the 148 industries.

GTBP has an Overall Score of 43. Find out what this means to you and get the rest of the rankings on GTBP!

See Full GTBP Report

What do These Ratings Mean?

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as “good” for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 43 means the stock is more attractive than 43 percent of stocks. Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes

InvestorsObserver

’s overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. There’s no need to try to remember what is “good” for a bunch of complicated ratios, just pay attention to which numbers are the highest.

What's Happening With GT Biopharma Inc Stock Today?

GT Biopharma Inc (GTBP) stock is down -0.33% while the S&P 500 is up 1.65% as of 2:26 PM on Thursday, Oct 14. GTBP is down -$0.02 from the previous closing price of $6.15 on volume of 102,638 shares. Over the past year the S&P 500 is higher by 27.15% while GTBP is up 80.29%. GTBP lost -$8.88 per share the over the last 12 months. Click Here to get the full Stock Report for GT Biopharma Inc stock.